Abstract: A nalmefene transdermal delivery system useful for the treatment of human patients suffering from opioid addiction.

Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after the device has been inserted in a patient by administering to the device a pharmaceutically effective amount of a composition having: (A) at least one taurinamide derivative, and (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.

Abstract: Disclosed are methods and compositions for treating proliferative disorders, such as cancers, blood vessel disorders, fibrotic disorders and acute or chronic rejection of transplanted organs, tissue or cells, using compounds of formula I or a tautomeric isomer thereof: wherein R1 and R2 are as defined; or a pharmaceutically-acceptable salt or pro-drug thereof.

Abstract: A method of using a ureido derivative of a poly-4-amino-2-carboxy-1-methyl pyrrole or a pharmaceutically acceptable salt thereof to inhibit inflammation, particularly non-TNF-&agr; dependent inflammation, in a mammal.

Abstract: Sesquiterpene epoxide compounds (trichothecenes) and methods for administering such compounds to achieve apoptotic ablation of internal organs or internal non-malignant cell populations are disclosed.

Abstract: Non-naturally occurring lytic peptides which contain a phenylalanine residue and one or more alanine, valine and lysine residues, and optionally contain chemically masked cysteine or serine residues possess an amphipathic structure which allows them to promote cell lysis in certain pathologic organisms, and particularly in prokaryotes. Peptides having a beta-pleated sheet secondary structure and lacking cysteine residues form one embodiment of these lytic peptides.

Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an antineoplastic vinca alkaloid derivative.

Abstract: A method and composition for the treatment of diabetic neuropathy is disclosed. The composition comprises a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant formulated in a pharmaceutically acceptable carrier. It has been found that this combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In view of the consensus in the art that effective combinations of various active agents have not been demonstrated to be effective for the treatment of diabetic neuropathy, the present invention provides a surprising and unexpected effect.

Abstract: Disclosed herein is a method for the purification of a saccharide, characterized in that, water and a feedstock solution containing at least L-arabinose and oligosaccharide where L-arabinose and/or xylose are/is the constituting component(s) obtained by hydrolysis of plant tissues are supplied to a chromatographic apparatus of a simulated moving-bed system where a solution can be circulated in one direction in an apparatus equipped with a packed bed in which an adsorbent is filled and the solution in the packed bed is moved in one direction whereupon at least L-arabinose and oligosaccharide are separated each other and concentration distribution of each of them is formed in the packed bed, then at least a concentrated L-arabinose solution and a concentrated oligosaccharide solution are extracted from the packed bed and, in addition, an inlet for the feedstock solution, an inlet for water, an outlet for the concentrated L-arabinose solution and an outlet for the concentrated oligosaccharide solution are succes

Abstract: Described herein are results which show that an endothelin receptor antagonist, BQ788, increases pigmentation and significantly reduces the viability of 7 human melanoma cell lines in culture. Moreover, it is described herein that administration of BQ788 significantly slows melanoma tumor growth in nude mice, including a complete growth arrest in half of the mice treated systemically. Thus, inhibitors of endothelin receptor activity are described herein as beneficial for the treatment of cancer.

Abstract: Methods for limiting apoptosis in a cell population by contacting such cells with a hydrophilic bile acid, such as ursodeoxycholic acid (UDCA), salts thereof, and analogs thereof (e.g., glyco- and tauro-ursodeoxycholic acid).

Abstract: The invention thus relates to a method for accelerating the rate of digestion of a protein matter, in which a protein matter is treated with transglutaminase, and it is mixed with anionic polysaccharides. The invention also relates to the use of the rapidly digested protein matter for preparing a food or pharmaceutical composition intended for oral administration to a mammal, to induce a postprandial peak of plasmatic increase in amino acids. This composition is intended for modulating the postprandial protein gain, limiting the problems linked to gastrointestinal motility disorders, limiting the postprandial sensations of nausea in pregnant women, and/or limiting the postprandial risks of regurgitation and/or gastro-esophageal reflux. Finally, a subject of the invention is also a food or pharmaceutical composition comprising anionic polysaccharides and a protein matter treated with transglutaminase.

Abstract: A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The method and device are especially useful in increasing alertness in individuals who are not readily responsive to usual external stimuli.

Abstract: A composition having antibacterial activity is disclosed. More particularly, a mixture of an oxazolidinone compound, sulbactam, and ampicillin active agents, demonstrating activity against resistant strains of bacteria is disclosed. Methods for using an oxazolidinone compound, sulbactam, and ampicillin to treat a bacterial infection are also described.

Abstract: The invention involves the identification of a family of compounds which block calcium channels. The compounds can be formulated in pharmaceutical carriers and administered to subjects. The compounds are useful for treating disorders associated with calcium channel activity, such as, cardiovascular diseases, for example hypertension, congestive heart failure, arrhythmia and angina.

Abstract: Nicotine dependency is treated by administration of an opioid antagonist. In some embodiments, rapid or ultra rapid detoxification techniques include using a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone or naltrexone or a mixture of any one of these, and either clonidine or related compounds either while awake, or while under sedation or anesthesia, followed by continued administration of an effective amount of an opioid antagonist with or without agents that enhance nicotine dependency treatment.

Abstract: A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1&agr;,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxic angents with the 1&agr;,24(S)-dihydroxyvitamin D2.

Abstract: The method of therapeutic management of sickle cell anemia involving oral administration to the patient of an effective dose of green tea polyphenols.

Abstract: Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.

Abstract: The present invention generally relates to various methods for treating the laminitis syndrome in animals. These benefits are obtained by administering to the animals a composition containing an &agr;-adrenergic antagonist that does not substantially cross the blood brain barrier. In one embodiment, the &agr;-adrenergic antagonist is domperidone. The domperidone can be administered to the animal either orally, subcutaneously, or intramuscularly and can be used to treat animals suffering from symptoms of laminitis.